INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 242 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $912,903 | +133.2% | 13,329 | +135.6% | 0.01% | +125.0% |
Q1 2024 | $391,534 | -3.7% | 5,658 | -0.3% | 0.00% | -20.0% |
Q4 2023 | $406,515 | +41.6% | 5,676 | +3.0% | 0.01% | +25.0% |
Q3 2023 | $287,172 | -17.3% | 5,513 | +0.6% | 0.00% | -20.0% |
Q2 2023 | $347,120 | +13.4% | 5,482 | -3.0% | 0.01% | +25.0% |
Q1 2023 | $306,164 | +2.9% | 5,654 | +0.6% | 0.00% | -20.0% |
Q4 2022 | $297,570 | +14.4% | 5,623 | +0.4% | 0.01% | 0.0% |
Q3 2022 | $260,000 | -7.8% | 5,601 | +13.5% | 0.01% | -16.7% |
Q2 2022 | $282,000 | +20.0% | 4,935 | +28.7% | 0.01% | +50.0% |
Q1 2022 | $235,000 | – | 3,834 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |